Cargando…

Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System

Objective: This study aimed to develop active surveillance programs (ASPs) for anaphylaxis using the China Hospital Pharmacovigilance System (CHPS) and analyze the characteristics, allergens, and management strategies for anaphylaxis within a tertiary hospital setting in China. Methods: We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chengcheng, Li, Zejing, Yu, Yingying, Feng, Maoyan, Liu, Anchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366353/
https://www.ncbi.nlm.nih.gov/pubmed/37497105
http://dx.doi.org/10.3389/fphar.2023.1180685
_version_ 1785077148226158592
author Wang, Chengcheng
Li, Zejing
Yu, Yingying
Feng, Maoyan
Liu, Anchang
author_facet Wang, Chengcheng
Li, Zejing
Yu, Yingying
Feng, Maoyan
Liu, Anchang
author_sort Wang, Chengcheng
collection PubMed
description Objective: This study aimed to develop active surveillance programs (ASPs) for anaphylaxis using the China Hospital Pharmacovigilance System (CHPS) and analyze the characteristics, allergens, and management strategies for anaphylaxis within a tertiary hospital setting in China. Methods: We retrospectively analyzed the anaphylaxis cases reported to the National Adverse Drug Reaction Monitoring System in our hospital from 2014 to 2021. Characteristic medical orders, progress notes, and diagnoses in these cases were recorded to identify initial anaphylaxis trigger entries. Based on these initial entries, the questionnaire was developed, and the Delphi method was used to establish consensus entries for anaphylaxis triggers. The CHPS was used to program these trigger entries and construct ASPs, which were then tested on the 238,194 discharged patients to evaluate their performance and analyze the related clinical data. Results: Ten anaphylaxis triggers and three ASPs were ultimately identified. The ASPs captured 309 cases, out of which 94 cases were confirmed as anaphylaxis following manual screening. After removing duplicates, we noted 76 patients who experienced anaphylaxis 79 times. The positive rate of triggers and the positive predictive value of the programs were 0.13% and 30.42%, respectively. The incidence of anaphylaxis in our study was 0.03%, and the number of anaphylaxis cases detected by the ASPs was 5.64 times higher than those detected by the spontaneous reporting system. Anaphylaxis was more common among female patients. Antibacterial drugs, antineoplastic drugs, and contrast media were the most prevalent allergens in clinical practice. Anaphylaxis to antineoplastic drugs had the highest incidence (0.6%) when compared with patients admitted during the same period. Our study revealed a significant underuse of epinephrine and overuse of second-line therapy (glucocorticoids and antihistamines) in the management of anaphylaxis. Furthermore, we found the use and dosage of epinephrine to be inappropriate. Conclusion: The CHPS can effectively utilize both structured and unstructured data to construct anaphylaxis ASPs, and this could counteract the under-reporting by the spontaneous reporting system, the primary adverse reaction monitoring method in China. The treatment and management of anaphylaxis are currently inadequate and require improvement to reduce mortality risk.
format Online
Article
Text
id pubmed-10366353
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103663532023-07-26 Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System Wang, Chengcheng Li, Zejing Yu, Yingying Feng, Maoyan Liu, Anchang Front Pharmacol Pharmacology Objective: This study aimed to develop active surveillance programs (ASPs) for anaphylaxis using the China Hospital Pharmacovigilance System (CHPS) and analyze the characteristics, allergens, and management strategies for anaphylaxis within a tertiary hospital setting in China. Methods: We retrospectively analyzed the anaphylaxis cases reported to the National Adverse Drug Reaction Monitoring System in our hospital from 2014 to 2021. Characteristic medical orders, progress notes, and diagnoses in these cases were recorded to identify initial anaphylaxis trigger entries. Based on these initial entries, the questionnaire was developed, and the Delphi method was used to establish consensus entries for anaphylaxis triggers. The CHPS was used to program these trigger entries and construct ASPs, which were then tested on the 238,194 discharged patients to evaluate their performance and analyze the related clinical data. Results: Ten anaphylaxis triggers and three ASPs were ultimately identified. The ASPs captured 309 cases, out of which 94 cases were confirmed as anaphylaxis following manual screening. After removing duplicates, we noted 76 patients who experienced anaphylaxis 79 times. The positive rate of triggers and the positive predictive value of the programs were 0.13% and 30.42%, respectively. The incidence of anaphylaxis in our study was 0.03%, and the number of anaphylaxis cases detected by the ASPs was 5.64 times higher than those detected by the spontaneous reporting system. Anaphylaxis was more common among female patients. Antibacterial drugs, antineoplastic drugs, and contrast media were the most prevalent allergens in clinical practice. Anaphylaxis to antineoplastic drugs had the highest incidence (0.6%) when compared with patients admitted during the same period. Our study revealed a significant underuse of epinephrine and overuse of second-line therapy (glucocorticoids and antihistamines) in the management of anaphylaxis. Furthermore, we found the use and dosage of epinephrine to be inappropriate. Conclusion: The CHPS can effectively utilize both structured and unstructured data to construct anaphylaxis ASPs, and this could counteract the under-reporting by the spontaneous reporting system, the primary adverse reaction monitoring method in China. The treatment and management of anaphylaxis are currently inadequate and require improvement to reduce mortality risk. Frontiers Media S.A. 2023-07-11 /pmc/articles/PMC10366353/ /pubmed/37497105 http://dx.doi.org/10.3389/fphar.2023.1180685 Text en Copyright © 2023 Wang, Li, Yu, Feng and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Chengcheng
Li, Zejing
Yu, Yingying
Feng, Maoyan
Liu, Anchang
Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
title Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
title_full Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
title_fullStr Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
title_full_unstemmed Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
title_short Active surveillance and clinical analysis of anaphylaxis based on the China Hospital Pharmacovigilance System
title_sort active surveillance and clinical analysis of anaphylaxis based on the china hospital pharmacovigilance system
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366353/
https://www.ncbi.nlm.nih.gov/pubmed/37497105
http://dx.doi.org/10.3389/fphar.2023.1180685
work_keys_str_mv AT wangchengcheng activesurveillanceandclinicalanalysisofanaphylaxisbasedonthechinahospitalpharmacovigilancesystem
AT lizejing activesurveillanceandclinicalanalysisofanaphylaxisbasedonthechinahospitalpharmacovigilancesystem
AT yuyingying activesurveillanceandclinicalanalysisofanaphylaxisbasedonthechinahospitalpharmacovigilancesystem
AT fengmaoyan activesurveillanceandclinicalanalysisofanaphylaxisbasedonthechinahospitalpharmacovigilancesystem
AT liuanchang activesurveillanceandclinicalanalysisofanaphylaxisbasedonthechinahospitalpharmacovigilancesystem